Abeona Therapeutics Total Assets 2006-2021 | ABEO

Abeona Therapeutics total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Abeona Therapeutics Annual Total Assets
(Millions of US $)
2020 $151
2019 $223
2018 $174
2017 $179
2016 $111
2015 $80
2014 $17
2013 $1
2012 $2
2011 $4
2010 $9
2009 $2
2008 $4
2007 $9
2006 $6
2005 $7
Abeona Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $119
2021-06-30 $131
2021-03-31 $141
2020-12-31 $151
2020-09-30 $159
2020-06-30 $164
2020-03-31 $175
2019-12-31 $223
2019-09-30 $143
2019-06-30 $159
2019-03-31 $166
2018-12-31 $174
2018-09-30 $161
2018-06-30 $167
2018-03-31 $176
2017-12-31 $179
2017-09-30 $96
2017-06-30 $97
2017-03-31 $105
2016-12-31 $111
2016-09-30 $74
2016-06-30 $74
2016-03-31 $77
2015-12-31 $80
2015-09-30 $90
2015-06-30 $77
2015-03-31 $13
2014-12-31 $17
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $1
2013-09-30 $1
2013-06-30 $2
2013-03-31 $2
2012-12-31 $2
2012-09-30 $1
2012-06-30 $2
2012-03-31 $3
2011-12-31 $4
2011-09-30 $2
2011-06-30 $5
2011-03-31 $7
2010-12-31 $9
2010-09-30 $2
2010-06-30 $4
2010-03-31 $5
2009-12-31 $2
2009-09-30 $3
2009-06-30 $2
2009-03-31 $4
2008-12-31 $4
2008-09-30 $6
2008-06-30 $7
2008-03-31 $7
2007-12-31 $9
2007-09-30 $4
2007-06-30 $4
2007-03-31 $5
2006-12-31 $6
2006-09-30 $7
2006-06-30 $8
2006-03-31 $11
2005-12-31 $7
2005-09-30 $8
2005-06-30 $9
2005-03-31 $12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.070B $0.010B
Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $119.040B 7.52
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.569B 21.29
Biohaven Pharmaceutical Holding (BHVN) United States $7.352B 0.00
Arcus Biosciences (RCUS) United States $3.077B 0.00
Emergent Biosolutions (EBS) United States $2.374B 8.53
Myovant Sciences (MYOV) United Kingdom $1.569B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.534B 0.00
Zymeworks (ZYME) Canada $0.936B 0.00
SQZ Biotechnologies (SQZ) United States $0.369B 0.00
Ambrx Biopharma (AMAM) United States $0.352B 0.00
Enzo Biochem (ENZ) United States $0.169B 16.57